Economic burden of atherosclerotic cardiovascular disease: a matched case–control study in more than 450,000 Swedish individuals

BMC Cardiovascular Disorders

Research

Michael Lyng Wolden¹  Mads Faurby¹  Kristoffer Nilsson²  Katarina Steen Carlsson³ 

[1] Novo Nordisk A/S, Søborg, Denmark;The Swedish Institute for Health Economics (IHE), Lund, Sweden;The Swedish Institute for Health Economics (IHE), Lund, Sweden;Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden;

关键词: Atherosclerotic cardiovascular disease;    Burden of illness;    Mortality;    Direct costs;    Indirect costs;   

DOI  :  10.1186/s12872-023-03518-y

 received in 2022-11-23, accepted in 2023-09-19,  发布年份 2023

来源: Springer

【 摘 要 】

AimTo examine direct and indirect costs, early retirement, cardiovascular events and mortality over 5 years in people with atherosclerotic cardiovascular disease (ASCVD) and matched controls in Sweden.MethodsIndividuals aged ≥ 16 years living in Sweden on 01 January 2012 were identified in an existing database. Individuals with ASCVD were propensity score matched to controls without ASCVD by age, sex and educational status. We compared direct healthcare costs (inpatient, outpatient and drug costs), indirect costs (resulting from work absence) and the risk of stroke, myocardial infarction (MI) and early retirement.ResultsAfter matching, there were 231,417 individuals in each cohort. Total mean per-person annual costs were over 2.5 times higher in the ASCVD group versus the controls (€6923 vs €2699). Indirect costs contributed to 60% and 67% of annual costs in the ASCVD and control groups, respectively. Inpatient costs accounted for ≥ 70% of direct healthcare costs. Cumulative total costs over the 5-year period were €32,011 in the ASCVD group and €12,931 in the controls. People with ASCVD were 3 times more likely to enter early retirement than controls (hazard ratio [HR] 3.02 [95% CI 2.76–3.31]) and approximately 2 times more likely to experience stroke (HR 1.83 [1.77–1.89]) or MI (HR 2.27 [2.20–2.34]).ConclusionASCVD is associated with both economic and clinical impacts. People with ASCVD incurred considerably higher costs than matched controls, with indirect costs resulting from work absence and inpatient admissions being major cost drivers, and were also more likely to experience additional ASCVD events.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 3

Fig. 2

Fig. 2